Additionally, the combination of CDK4 and MAPK pathway inhibitors has shown tumor regression in xenograft models of cancers with KRAS, NRAS, or BRAF mutations, particularly BRAF- and NRAS-mutant melanoma, with promising results from phase I clinical studies (29, 48–52). This evidence concerns the gene KRAS and neoplasm.